PDF(Pubmed)
Abstract：
BACKGROUND: Seroprevalence studies about chikungunya infection are usually conducted after epidemics to estimate the magnitude of the attack. This study aimed to estimate the seroprevalence of CHIKV by WHO region, considering the periods of introduction of the virus in these regions and its potential to lead to epidemics.
METHODS: We systematically reviewed Medline/Pubmed, Embase, Lilacs, Scopus and Web of Science for original articles published up to 2020. Cohort, case-control and cross-sectional studies were eligible for inclusion, based on the results of laboratory diagnosis of previous or previous and recent infection. Those conducted with symptomatic individuals were excluded.
RESULTS: 596 articles were identified, 197 full-text were reviewed and 64 were included, resulting in 71 seroprevalences. Most were cross-sectional studies (92%), between 2001 and 2020 (92%), with population of all ages (55%), conducted in Kenya (10.9%), Brazil (9.4%) and French Polynesia (7.8%). The pooled estimates were 24% (95%CI 19-29; I2 = 99.7%; p < 0.00), being 21% (95%CI 13-30; I2 = 99.5%; p < 0.00) for adults, 7% (95%CI 0-23; I2 = 99.7%; p < 0.00) for children and 30% (95%CI 23-38; I2 = 99.7%; p < 0.00) for all ages. The higher seroprevalences were found in African, the Americas and South-East Asian Regions.
CONCLUSIONS: The great heterogeneity of seroprevalences points to the persistence of viral circulation. Even where the seroprevalence is high, the population replacement and the absence of vaccines mean that the risk of virus spread and epidemics remains.
BACKGROUND: PROSPERO CRD42020166227.
METHODS: We systematically reviewed Medline/Pubmed, Embase, Lilacs, Scopus and Web of Science for original articles published up to 2020. Cohort, case-control and cross-sectional studies were eligible for inclusion, based on the results of laboratory diagnosis of previous or previous and recent infection. Those conducted with symptomatic individuals were excluded.
RESULTS: 596 articles were identified, 197 full-text were reviewed and 64 were included, resulting in 71 seroprevalences. Most were cross-sectional studies (92%), between 2001 and 2020 (92%), with population of all ages (55%), conducted in Kenya (10.9%), Brazil (9.4%) and French Polynesia (7.8%). The pooled estimates were 24% (95%CI 19-29; I2 = 99.7%; p < 0.00), being 21% (95%CI 13-30; I2 = 99.5%; p < 0.00) for adults, 7% (95%CI 0-23; I2 = 99.7%; p < 0.00) for children and 30% (95%CI 23-38; I2 = 99.7%; p < 0.00) for all ages. The higher seroprevalences were found in African, the Americas and South-East Asian Regions.
CONCLUSIONS: The great heterogeneity of seroprevalences points to the persistence of viral circulation. Even where the seroprevalence is high, the population replacement and the absence of vaccines mean that the risk of virus spread and epidemics remains.
BACKGROUND: PROSPERO CRD42020166227.
摘要：
背景：关于基孔肯雅热感染的血清阳性率研究通常在流行后进行，以估计发作的程度。这项研究旨在估计世界卫生组织地区CHIKV的血清阳性率，考虑到这些地区引入病毒的时期及其导致流行病的潜力。
方法：我们系统地回顾了Medline/Pubmed，Embase,丁香花,Scopus和WebofScience提供截至2020年发表的原创文章。队列,病例对照和横断面研究符合纳入条件，基于先前或先前和最近感染的实验室诊断结果。与有症状的个体进行的那些被排除在外。
结果：确定了596篇文章，共审查了197份全文，纳入了64份全文，导致71个血清恢复。大多数是横断面研究（92%），2001年至2020年（92%），所有年龄段的人口（55％），在肯尼亚进行（10.9%），巴西（9.4%）和法属波利尼西亚（7.8%）。汇总估计值为24%(95CI19-29；I2=99.7%；p<0.00)，成人为21%（95CI13-30；I2=99.5%；p<0.00），儿童为7%（95CI0-23；I2=99.7%；p<0.00），所有年龄段为30%（95CI23-38；I2=99.7%；p<0.00）。在非洲发现了更高的血清阳性率，美洲和东南亚地区。
结论：血清效价的巨大异质性表明病毒循环的持续性。即使血清阳性率很高，人口替代和缺乏疫苗意味着病毒传播和流行病的风险仍然存在。
背景：PROSPEROCRD42020166227.
方法：我们系统地回顾了Medline/Pubmed，Embase,丁香花,Scopus和WebofScience提供截至2020年发表的原创文章。队列,病例对照和横断面研究符合纳入条件，基于先前或先前和最近感染的实验室诊断结果。与有症状的个体进行的那些被排除在外。
结果：确定了596篇文章，共审查了197份全文，纳入了64份全文，导致71个血清恢复。大多数是横断面研究（92%），2001年至2020年（92%），所有年龄段的人口（55％），在肯尼亚进行（10.9%），巴西（9.4%）和法属波利尼西亚（7.8%）。汇总估计值为24%(95CI19-29；I2=99.7%；p<0.00)，成人为21%（95CI13-30；I2=99.5%；p<0.00），儿童为7%（95CI0-23；I2=99.7%；p<0.00），所有年龄段为30%（95CI23-38；I2=99.7%；p<0.00）。在非洲发现了更高的血清阳性率，美洲和东南亚地区。
结论：血清效价的巨大异质性表明病毒循环的持续性。即使血清阳性率很高，人口替代和缺乏疫苗意味着病毒传播和流行病的风险仍然存在。
背景：PROSPEROCRD42020166227.
